{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:12:07Z","timestamp":1794316327584,"version":"4.9.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the number of physicians credentialed to prescribe buprenorphine has increased over time, many credentialed physicians may be reluctant to treat individuals with opioid use disorders due to discomfort with prescribing buprenorphine. Although prescribing physicians are required to complete a training course, many have questions about buprenorphine and treatment guidelines have not been updated to reflect clinical experience in recent years. We report on an expert panel process to update and expand buprenorphine guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified candidate guidelines through expert opinion and a review of the literature and used a modified RAND\/UCLA Appropriateness Method to assess the validity of the candidate guidelines. An expert panel completed 2 rounds of rating, with a meeting to discuss the guidelines between the first and second ratings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through the rating process, expert panel members rated 90 candidate guideline statements across 8 domains, including candidacy for buprenorphine treatment, dosing of buprenorphine, psychosocial counseling, and treatment of co-occurring depression and anxiety. A total of 65 guideline statements (72%) were rated as valid. Expert panel members had agreement in some areas, such as the treatment of co-occurring mental health problems, but disagreement in others, including the appropriate dosing of buprenorphine given patient complexities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Through an expert panel process, we developed an updated and expanded set of buprenorphine treatment guidelines; this additional guidance may increase credentialed physicians\u2019 comfort with prescribing buprenorphine to patients with opioid use disorders. Future efforts should focus on appropriate dosing guidance and ensuring that guidelines can be adapted to a variety of practice settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2015.1012613","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T11:59:00Z","timestamp":1428321540000},"page":"209-216","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of\u00a0an\u00a0Expert Panel Process"],"prefix":"10.1177","volume":"36","author":[{"given":"Carrie M.","family":"Farmer","sequence":"first","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Institute for Research, Education, and Training in Addictions, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Williams","sequence":"additional","affiliation":[{"name":"Institute for Research, Education, and Training in Addictions, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ayers","sequence":"additional","affiliation":[{"name":"Community Care Behavioral Health Organization, University of Pittsburgh Medical Center Insurance Division, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Schuster","sequence":"additional","affiliation":[{"name":"Community Care Behavioral Health Organization, University of Pittsburgh Medical Center Insurance Division, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Cilia","sequence":"additional","affiliation":[{"name":"Community Care Behavioral Health Organization, University of Pittsburgh Medical Center Insurance Division, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Clinical Practice, Murrysville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Mandell","sequence":"additional","affiliation":[{"name":"Community Substance Abuse Centers, Westfield, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"},{"name":"Center for Health Equity Research and Promotion, Mental Illness Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"bibr1-08897077.2015.1012613","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), US Department of Health and Human Services. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: SAMHSA; 2013."},{"key":"bibr2-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"bibr3-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.018"},{"key":"bibr4-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-011-0222-2"},{"key":"bibr5-08897077.2015.1012613","unstructured":"American Methadone Treatment Association. Methadone Maintenance Program and Patient Census in the U.S. New York: American Methadone Treatment Association; 1998."},{"key":"bibr6-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.004"},{"key":"bibr7-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-3-17"},{"key":"bibr8-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00194-6"},{"key":"bibr9-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.12.008"},{"key":"bibr10-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0806-7"},{"key":"bibr11-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.03.010"},{"key":"bibr12-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.01.009"},{"key":"bibr13-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2011.01.032"},{"key":"bibr14-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.10.016"},{"key":"bibr15-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1080\/10550490802408613"},{"key":"bibr16-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1080\/10550490902931373"},{"key":"bibr17-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1037\/a0022776"},{"key":"bibr18-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1377-y"},{"key":"bibr19-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0264-7"},{"key":"bibr20-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1595"},{"key":"bibr21-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.04.008"},{"key":"bibr22-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.06.006"},{"key":"bibr23-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2014.12143.x"},{"key":"bibr24-08897077.2015.1012613","unstructured":"Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004."},{"key":"bibr25-08897077.2015.1012613","unstructured":"McNicholas L. Personal communication to Bradley D. Stein; 2011."},{"key":"bibr26-08897077.2015.1012613","unstructured":"Center for Substance Abuse Treatment. Buprenorphine: A Guide for Nurses. Washington, DC: Substance Abuse and Mental Health Services Administration; 2009. DHHS Publication No. (SMA) 09-4376."},{"key":"bibr27-08897077.2015.1012613","unstructured":"Department of Veteran's Affairs. VA\/DoD Clinical Practice Guideline for Management of Substance Use Disorders. Washington, DC: US Department of Defense; 2009."},{"key":"bibr28-08897077.2015.1012613","unstructured":"Department of Veteran's Affairs Affairs. VA\/DoD Clinical Practice Guideline for Management of Substance Use Disorder (SUD). Washington, DC: US Department of Defense; 2009."},{"key":"bibr29-08897077.2015.1012613","unstructured":"Vermont Department of Health Division of Alcohol and Drug Abuse Programs (VDH\/ADAP), Office of Vermont Health Access (OVHA). Vermont Buprenorphine Practice Guidelines. Morrisville, VT: Author; 2010."},{"key":"bibr30-08897077.2015.1012613","volume-title":"Criteria for Use of Buprenophine\/Naloxone and Buprenorphine Sublingual Tablets","author":"Goodman F","year":"2007"},{"key":"bibr31-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2012.06.006"},{"key":"bibr32-08897077.2015.1012613","unstructured":"Shuster J. Community care behavioral health organization [personal communication]; 2011."},{"key":"bibr33-08897077.2015.1012613","volume-title":"The RAND\/UCLA Appropriateness Method User's Manual","author":"Fitch K","year":"2001"},{"key":"bibr34-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj438"},{"key":"bibr35-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.8.807"},{"key":"bibr36-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1037\/h0080151"},{"key":"bibr37-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000298371"},{"key":"bibr38-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190043026"},{"key":"bibr39-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182312983"},{"key":"bibr40-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01731.x"},{"key":"bibr41-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1177\/0163278711407313"},{"key":"bibr42-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12024.x"},{"key":"bibr43-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1176\/ps.62.8.pss6208_0963"},{"key":"bibr44-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007111"},{"key":"bibr45-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-010-9352-y"},{"key":"bibr46-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-26"},{"key":"bibr47-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-7-62"},{"key":"bibr48-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3180473c11"},{"key":"bibr49-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.12.005"},{"key":"bibr50-08897077.2015.1012613","unstructured":"Maxwell JC. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators. Substance Abuse and Mental Health Services Administration; 2006. Available at: http:\/\/buprenorphine.samhsa.gov."},{"key":"bibr51-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711104010028"},{"key":"bibr52-08897077.2015.1012613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2009.08.001"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1012613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2015.1012613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1012613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:46:03Z","timestamp":1777625163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2015.1012613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1080\/08897077.2015.1012613"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2015.1012613","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}